Protagonist Therapeutics, Inc. (PTGX) Profit Margins
Over the twelve months to 2026-06-30, Protagonist Therapeutics, Inc. (PTGX) had operating margin 20.7%, net margin 29.4%, free cash flow margin 46.3%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PTGXProtagonist Therapeutics, Inc.Follow PTGX — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 135.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -136.7% | -34857.6% | -225.4% | -460.0% | -494.2% | -156.1% | 58.2% | -343.6% | 20.7% | |
| Net margin | -125.9% | -33414.3% | -231.1% | -458.9% | -479.3% | -131.6% | 63.3% | -282.8% | 29.4% | |
| FCF margin | -163.1% | -18395.7% | -254.8% | -398.3% | -409.8% | -118.1% | 42.1% | 121.9% | 46.3% |
USD millions · SEC XBRL
Protagonist Therapeutics, Inc. — questions
- What is Protagonist Therapeutics, Inc.'s operating margin?
- 20.7% over the twelve months to 2026-06-30.
- What is Protagonist Therapeutics, Inc.'s net profit margin?
- 29.4% over the twelve months to 2026-06-30.
Every figure on this page comes from Protagonist Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.